Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hear you Gator. I still would have liked the PR to end that the trial is ending due to statistical significance. (w/o the likely being met). I'll be around waiting to see if we can get anything like a Tamiflu drug or possibly a partnership for a long covid study, but I'm not holding my breath anymore. If this stuff works for symptoms, like we think it will, we will likely get our money back. No point in selling for peanuts now.
ps. I still don't understand what is being unblinded. Didn't they unblind the 210 and recently look at 510? What is left? Maybe they are now looking specifically at symptoms for the 720 and the FDA will let it slide for a cold remedy. Other uses are there as well.
pps. We now have a 6 and dealer is showing an ace. Ugh.
ppps. Why not wait some more? Nothing more to lose now.
News out. The fly speaks...
https://www.stocktitan.net/news/RVVTF/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-3x0it6c60rx7.html
ps. Endpoints suck. We knew that... More unblinding? What did they look at? Confused at the moment.
Nobody was stopping anything when viewing 210 patients. With the addition of 500 dosed at higher levels of Buccy, and a surge in covid cases, one can hope that it's zero for buccy and nine for the placebo. That's all. You can't blame a guy for hoping and believing. With capital running out, Revive needs a partnership and the only way to that agreement is solid data.
ps. GLTA
That is my understanding, although Revive doesn't own the rights to Buccy in a few places in Asia, but, I believe, the rest of the world is fair game.
ps. We wait.
I tend to agree with everything you stated, but the hail mary pass is that Buccy had no hospitalizations and the placebo group had eleven.
Was MF in a good mood this evening? Did he play golf, smoke a stogie, etc. ? Rubber, where is that fly on the wall?
I'm looking for volume of 500,000 tomorrow.
ps. We will know soon enough, likely within seven days.
Allow me to be the first to kick off the festivities for tomorrow. MF will be schmoozing in the morning with the DSMB to get this product to market in the states. After analyzing the amazing data, there will be a slight leak as volume mounts in the afternoon. Within one week, MF drops a press release with the results of the trial. If Revive continues the trial with a partner, so be it. If they get bought out, good. If the trial was a flop, it is an expensive lesson and a few more years of hard work.
ps. Yes. I am the king of $2 lunches, Gator.
pps. I expect to hear from Rubber, Blue, All, Cool, Eco, Gator, Nosnibor and others as we start getting psyched up for the results of the 720 patients. One episode will certainly end within a week. Will another begin? It's anyone's guess. GLTA. (even Snoopy)
Alex- I'll take Bucillamine for $.20.
ps. Now Alex is gone.
pps. It was easier to laugh back then.
ppps. Good luck to all. (even Snoopy)
May 17th can not come soon enough. There is no excitement, based on the pps, as the longs hold and the rest of the world remains nonbelievers.
ps.It will be nice to finally see the results of the patients who took the higher dosage of Buccy. We have been waiting for quite some time.
That's a good catch. Unfortunately, that is the outcome we most desire. I think it may have to do with the endpoint switch back to hospitalizations. Unlike McDonalds, the FDA is not lovin it.
ps. Good data opens the door to so many pathways that it is hard not to get excited. I like the addition of symptom data, but I think Revive didn't accumulate exactly what the FDA wants so there still needs to be negotiations and discussions. This is where we could use some expertise.
NEWS OUT.
https://www.globenewswire.com/news-release/2023/05/02/2658886/0/en/Revive-Therapeutics-Announces-Data-Safety-Monitoring-Board-Meeting-Date-on-Phase-3-Clinical-Study-of-Bucillamine-in-the-Treatment-of-COVID-19.html?fbclid=IwAR3hk1InFM3Kt6I--6ciptfu6KhhmK0pV1Gwf2tpGsBoi7BWj4gWSuolhoE
I am pleasantly surprised the the data has already been submitted and the timelines are very soon. Let's see.
Scrub, rinse, soak, clean, sanitize, prepare and get this data to the DSMB so the big boys can swoop on in and finish this trial for long haulers. Get Buccy to market for several infectious diseases in the USA and let's move things along. The fat lady has not sung yet, but she is now standing on stage and the stage is a rockin.
ps. Revive has taken a couple of body blows, but it just takes one good left hook to get back in the game. Come on MF. Get er done.
I watched the podcast and appreciate the efforts of all involved. I have two thoughts:
1. I am not interested in what I believe to be frivolous lawsuits. We all knew the risks, and I still hold out hope that this can work.
2. I found the part where BMT spoke about partnerships quite interesting. He claims that negotiations are not likely due to RVVT pursuing endpoints of hospitalization when even if the data proves Bucy had none, the world has changed one and a half years later making the data antiquated. He believes that if he was guided by an outside source, a focus would have been more on symptoms for long covid. Then he mentions he may intentionally being misled so after a denial or recommendation of trial continuation by DMSB, RVVTF could be bought at a cheaper price.
He also cites that countries have a stockpile of Pax. These thoughts are troublesome.
ps. I still have hope that if we hit a wall, Bucy as a universal drug will get us back to a green pasture. I'm looking forward to unblinding to see what we have here. Also, MF will not even consider this "Chris" addition.
Hang in there, buddy. I've seen horses finish first without a jockey.
ps. I just realized they are disqualified, but you see my point. lol.
pps. As cash depletes, a partnership is growing more and more likely and more and more imminent.
Agree. This is the first time we heard it from the big cheese.
Boys- There is one thing that I can't get straight in my head. Well, lots of things but that is a story for another day. I get that continuing the trial is going to be tough with the current endpoints..... but.... The 710 were done with primarily the Delta Variant upon which hospitalizations were quite high and the last 500 were done with higher doses of Buccy. Even with many getting the placebo and a third getting the dosage the same as the 210, that should tell is something definitive. I guess the argument is that a few patients can swing the vote one way or another and more data would need to be collected. Any thoughts?
ps. Let's go dmsb. Ship this thing through quickly.
Hey, Blue. Good day in Frankfort. Come on, we have to get excited about something. It's a funny way to respond to a letter, agreed, but I think we are finally on the right track.
I dig the PR and it is clear MF received the said letter. I hear unblinding and partnership, and I am getting optimistic again.
ps. Let's see.
Lol. You have an excellent memory, Rubber. She does not really understand the concept of owning stocks. She is still holding it and doesn't quite understand what she owns, but I slipped her $100, so that in case of Armageddon, I still remain her favorite uncle
ps. I saw that Merck bought out a company today for, I believe, 11 billion or some crazy number and I peeked, hoping it to be Revive, but until will unblind, nobody knows the extent that Bucillamine works. Yes, there are lots of studies, but big pharm needs clinical studies.
pps. Release the Beast. #Bucy.
I liked the memo until I read the ending again. This will piss off the big guy and hinder getting a solid response.
If all other avenues have been exhausted, it is time to bring on an executive with relevant experience in the pharmaceutical industry to tap into Bucillamine’s potential. We are in discussions with promising candidates and are prepared to offer a recommendation if an experienced candidate for CEO has not been identified by the board.
Cool- You're one of my favorite posters. You always find unique and relative items. Now if you can please find a path to recoup some of our loses, the longs will be much obliged.
My understanding is that he replied that he will answer questions so BMT et al. is compiling a list of questions and prioritizing them based on the number of responses they receive from investors.
Good to know. I'd like to see exactly what the plan is as Revive moves forward. All I know is I paid a lot of money to see the trial unblinded by now and I still wait.
You're a poet and you didn't even know it.
True.
ps. I got nothing these days.
pps. Saw the MF letter. He likely will tell shareholders to read the PR again.
ppps. Does the study continue for hospitalization or can Revive go back and contact the patients and use that as part of a long hauler study?
News out on the other side: First patient enrolled.
https://revivethera.com/2023/03/revive-therapeutics-provides-update-on-psilocybin-clinical-study-for-methamphetamine-use-disorder/
Put me down for wanting the stock to go up. If this continues, my next ditch to dig may be my own.
ps. Not looking at the stock 50 times a day anymore; I only check it about 15 hoping for a buyout miracle or something to cheer about.
If Revive is continuing the trial maybe they can add symptoms check this time to the protocol and give the FDA what they want for the next 700 patients. Nobody is going to the hospital whether they gulp down a placebo or Buccy.
ps. I hope none of us longs die before we are unblinded. That would suck.
Hey Blue. I was wondering when you would chime in today. Gator and Gio, as stated by Rubber, are like me. They are stewing about the pps, the delays of unblinding the data and several dozen other things I can think of but don't care to list. It just a long term hold for me,but very likely about 7 more years at work than I intended. Unless a miracle appears from some big Pharm savior, all the other stuff is just too far away to get excited.
ps. Rio- If you read this, your posts were always informative. I'm curious if you moved on- I can't blame you.
pps. Here is my new blackjack analogy. We have a 16 and the dealer has an Ace. Maybe a long term covid possibility, but I can't even think right now. I keep telling myself it's just a paper loss. Ugh.
I'm disappointed today more than most. I couldn't even follow the stock after the initial selloff. No point in selling here. I just hope to make some money back in time and maybe close the year at a dime. Who knows? Holding but not expecting greatness anymore. I lost a lot today on paper. Like others selling at $.70 would have made too much sense. Ugh.
For those who haven't seen the numbers: It makes you worse.
#Paxlovid effect on reducing #COVID19 hospitalizations in vaccinated population finally revealed to the public by FDA. #IDTwitter 0.9% (3/317) paxlovid vs. 2.2% (7/314) placebo
Sorry to hear that Rubber. I trust, if we can get thing this to market, your problems will be lessened.
ps. I don't know if Bucy can help with your mother in law, though.
GLTA.
ps. Someday, somewhere, something soon will happen.
Ok, Michael Frank. The ball has been passed back to your hands. Take your time to cross your t's and dot your i's. Give the FDA exactly what they want, and put a bow on it. The FDA is not keeping us around because they are nice guys. Clearly, the data is amazing and the unblinding of the next 500 at higher doses will be even better. At this point, all resources and efforts need to be put into this venture. When the new endpoints are submitted, then you may play golf. Until that time, ten hour days with thirty minutes for lunch is all I can give you. Let's make this happen.
I read your article. So it appears that a specific trial is going to have to be done to determine if Bucillamine works for long haulers. It's not enough to just go back and ask each person about symptoms now, It has to be in the design. With fewer people getting covid, patients are going to be hard to find. I still believe in this stock although this has clearly gone on too long for us to make what we originally anticipated. Cheers to unblinded the final 500 and show the world that this drug is boss for many infectious diseases including covid. I hope I am wrong about long haulers. Unblinding and a buyout will still be a nice return.
This is getting worrisome. MF needs help from financial and data experts. What the heck happened to the FDA guiding his hand at the "C" meeting and spoon feeding him what needs to be submitted as we were fast tracked to phase 3? Like a previous poster stated, it's good to be in the game, but this was a waste of a few months. The next PR will be about Cannabis. I am done with my rant.
ps. Waiting along with the rest of you guys.
We will have to wait longer, but we are still in the game to cover infectious diseases including COVID and Long Haulers. I am a little disappointed because I thought some of this was worked out with the Level "C" meeting.
ps. Ugh. Wait some more.
I hate after hour news.
ps. Unless it's really good.
All good, buddy. Let's go............................
Revive is Canadian? I thought they moved to the USA 6 months ago? Sheesh. Markets have nothing to do with this small Canadian stock. This stock will live or die based on the markets reaction to the data, endpoints and EUA, etc specific to $RVVTF. The whole world could collapse or the markets could shoot to the moon, but for Revive, it's all about their intellectual property and Bucillamine.
ps. Let's go for a ride north.
pps. To the gentleman who spoke of no leaks, that is somewhat troubling to me too, but I trust market makers are keeping this low for a reason. That's what word on the street is all about.
ppps. tick tock tick tock
Ha. Many eyes are watching right now. Yes. Something is going to break one way or the other. The 210 data must be amazing to have gone this far. Let's keep the faith.
ps. Gator for VP of Revive.